BBlogFlow

Development and internal validation of a clinical risk score for early delirium detection in older emergency department patients - Nature

·11h ago

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.

AbstractDelirium is a common but frequently underrecognized neuropsychiatric syndrome among older adults in the emergency department (ED), associated with prolonged hospitalization and increased mortality. To develop a clinical risk score for early delirium detection in older emergency department patients. We conducted a prospective cohort study in the ED of a tertiary hospital from July 2024 to July 2025. Patients aged ≥ 65 years who remained in the ED for > 4 h were assessed using the Thai version of the Confusion Assessment Method intensive care unit (CAM-ICU) within 12 h of arrival. Demographic data, comorbidities, functional status, medications, presenting features, vital signs, laboratory values, and ED diagnoses were collected. Multivariable logistic regression was used to derive a clinical risk score, which was evaluated area under the receiver operating characteristic curve (AuROC).

This article is an excerpt. To read the full content, visit the original source. Nature

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Medical Xpress·

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.

Oncodaily·